Addition of atomoxetine for depression incompletely responsive to sertraline: A randomized, double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 68, Issue 4, 2007, Pages 582-587

  Michelson, David ^a,b,i   Adler, Lenard A ^c   Amsterdam, Jay D ^d   Dunner, David L ^e   Nierenberg, Andrew A ^f   Reimherr, Frederick W ^g   Schatzberg, Alan F ^h   Kelsey, Douglas K ^a   Williams, David W ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO; SERTRALINE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 34247470174     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0414     Document Type: Article

References (16)

1. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-511
2. Nelson JC. Treatment of refractory depression. Depress Anxiety 1997;5: 165-174
3. Potter WZ, Schmidt ME. Noradrenergic and other new antidepressants. In: Halbreich U, Montgomery S, eds. Pharmacotherapy for Mood, Anxiety and Cognitive Disorders. Washington, DC: American Psychiatric Press; 2000:237-254
4. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55:296-300
5. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
6. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374
7. Carpenter L. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry 2005;66:1234-1238
8. First MB, Spitzer GM, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2000
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
10. World Medical Association. Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects, 2000. Available at: http://www.wma.net/e/policy/b3.htm. Accessibility verified February 5, 2007
11. Maier W, Philipp M. Improving the assessment of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985;18:114-115
12. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Bethesda, Md: US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md. National Institute of Mental Health; 1976:218-222
13. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-590
14. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. NeuroReport 2000;11:215-219
15. Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383-386
16. Murphy GM Jr, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-1169